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Diagnostic techniques based on PCR have two major problems: false-positive reactions due to contamination
with DNA fragments from previous PCRs (amplicons) and false-negative reactions caused by inhibitors that
interfere with the PCR. We have improved our previously reported PCR based on the amplification of a
fragment of the Mycobacterium tuberculosis complex-specific insertion element IS6110 with respect to both
problems. False-positive reactions caused by amplicon contamination were prevented by the use of uracil-N-
glycosylase and dUTP instead of dTTP. We selected a new set of primers outside the region spanned by the
formerly used primers to avoid false-positive reactions caused by dTTP-containing amplicons still present in
the laboratory. With this new primer set, 16 copies of the IS6110 insertion element, the equivalent of two
bacteria, could be amplified 1010 times in 40 cycles, resulting in a mean efficiency of 77% per cycle. To detect
the presence of inhibitors of the Taq polymerase, which may cause false-negative reactions, part of each sample
was spiked with M. tuberculosis DNA. The DNA purification method using guanidinium thiocyanate and
diatoms effectively removed most or all inhibitors of the PCR. However, this was not suitable for blood samples,
for which we developed a proteinase K treatment followed by phenol-chloroform extraction. This method
permitted detection of 20 M. tuberculosis bacteria per ml of whole blood. Various laboratory procedures were
introduced to reduce failure or inhibition of PCR and avoid DNA cross contamination. We have tested 218
different clinical specimens obtained from patients suspected of having tuberculosis. The samples included
sputum (n = 145), tissue biopsy samples (n = 25), cerebrospinal fluid (n = 15), blood (n = 14), pleural fluid
(n = 9), feces (n = 7), fluid from fistulae (n = 2), and pus from a wound (n = 1). The results obtained by PCR
were consistent with those obtained with culture, which is the "gold standard." We demonstrate that PCR is
a useful technique for the rapid diagnosis of tuberculosis at various sites.
Timely identification of infection with Mycobacterium tuber-
culosis is important because of the need to make decisions
regarding management such as beginning antituberculosis drug
therapy, isolation precautions, and prophylaxis. The outcome
for the patient could be improved if fast, simple, and reliable
tests could be developed. The diagnosis of extrapulmonary
tuberculosis and tuberculoid meningitis is difficult, and the
definitive diagnosis depends on culture of the mycobacteria,
which is time-consuming and not always available.
We and others have recently reported on the use of PCR for
the detection and identification of M. tuberculosis complex in
clinical samples (2-5, 7, 8, 13, 19, 22, 23, 25). This is a rapid and
sensitive technique. The exquisite sensitivity of the PCR may
also be a drawback: contamination of the laboratory with
amplified DNA from previous PCRs (amplicons) may cause
false-positive results. In this paper, we describe the use of
uracil-N-glycosylase (UNG) (10) and dUTP instead of dTTP to
prevent false-positive results due to amplicon contamination.
We have extended our work on the quality control of the
performance of PCR and have developed a DNA purification
method for blood and feces samples. We have used this
technically improved PCR in clinical samples from patients
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suspected of having tuberculosis by comparing the PCR results
with the results of Ziehl-Neelsen (ZN) staining and culture.
MATERIALS AND METHODS
Bacterial strains. The same mycobacterial and nonmycobac-
terial strains as described previously (8) were used for the
specificity testing.
Clinical samples. Sputum samples from 92 patients sus-
pected of having tuberculosis were obtained from the Tuber-
culosis Division, Bangkok, Thailand. Samples were transported
by air at - 20°C. The other clinical samples were sent from
various university hospitals in The Netherlands and included
sputum (n = 53), tissue biopsy samples (n = 25), cerebrospinal
fluid (n = 15), EDTA-blood (n = 14), pleural fluid (n = 9),
feces (n = 7), fluid from fistulae (n = 2), and pus from a wound
(n = 1). All samples were kept at -20°C.
Decontamination of sputum for culture. The sputum sam-
ples from Bangkok were decontaminated with oxalic acid. A
swab was inserted into the sputum sample and then placed in
5% oxalic acid for 20 min at 25°C. The swab was then
incubated in 5% Na citrate for 10 min at 25°C.
The sputum samples from The Netherlands were decontam-
inated, depending on the preference of the laboratory, by the
NaOH Petroff method (6, 15), by the sodium laurylsulfate
method (6, 16), or with NaOH-sodium citrate-N-acetyl-L-
cysteine (9, 24). In all these cases, samples were concentrated
by centrifugation after decontamination.
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ZN staining. At the Tuberculosis Division in Bangkok,
sputum smears were microscopically examined after ZN stain-
ing (20). In the laboratories in The Netherlands all clinical
samples were microscopically examined after ZN staining after
being concentrated.
Routine culture. In Bangkok, sputum samples were cultured
on two Lowenstein-Jensen slants. In the laboratories in The
Netherlands, sputum samples were cultured on two different
solid media, Lowenstein-Jensen and Colletsos or Ogawa. The
samples from patients suspected of having extrapulmonary
tuberculosis were cultured in addition on liquid medium,
Middlebrook 7H9 broth (Difco Laboratories, Detroit, Mich.)
and/or MB-Check (Roche) M, a combined liquid and three
solid media (Hoffman-La Roche, Basel, Switzerland). The
specimens were incubated at 37°C for 2 months and examined
weekly for growth.
Pretreatment of clinical samples containing blood. Clinical
samples which contained visible traces of blood were treated
with a lysis buffer consisting of 1% Triton X-100 in 20 mM
Tris-HCl (pH 8.3) as previously described (8).
DNA purification from clinical samples. Clinical samples
(other than sputum, tissue biopsy samples, blood, and feces)
and decontaminated (9) sputum pellets (100 p.I) were mixed
with 900 p.l of a lysis buffer containing approximately 5 M
guanidinium thiocyanate, 1% Triton X-100, 50 mM Tris-HCl
(pH 6.4), and 20 mM EDTA (L6 lysis buffer [1]). DNA was
purified according to the guanidinium thiocyanate method
using 20 p.l of diatoms (1). DNA was eluted from the diatoms
in two steps with 60 and 40 pul of Tris-EDTA (TE) buffer (10
mM Tris-HCl [pH 8.3], 1 mM EDTA).
Treatment of biopsy samples. Biopsy samples (1 to 15 mg)
were incubated for 1 h at 60°C in a mixture of 0.1 mg of
proteinase K per ml, 0.5% Triton X-100, and 20 mM Tris-HCl
(pH 8.3). The biopsy material was further disrupted by adding
900 p.l of L6 lysis buffer and 500 of zirconium beads (0.1-mm
diameter) (Biospec Products, Bartlesville, Okla.). The mixture
was shaken in a mechanical disruptor (MiniBeadBeater model
3110; Biospec Products) for 3 min. After the zirconium beads
had settled, the DNA was purified from the supernatant by the
guanidinium thiocyanate method (1).
Treatment of blood and feces. Blood and feces were treated
essentially as described by Meredith and coworkers (12).
EDTA-blood (600 p.l) or feces (600 p.l) was mixed with 250
of TE buffer and incubated with 100 pul of a 10-times-
concentrated stock proteinase K digestion buffer (1 mg of
proteinase K per ml, 5% Triton X-100, and 200 mM Tris-HCl
[pH 8.3]) for 1 h at 60°C. DNA was isolated from the digest hy
phenol-chloroform extraction. A volume of 950 of phenol
(saturated with 100 mM Tris-HCl [pH 8.3]) was added. After
10 min of shaking on a gyratory shaker at 100 rpm, the mixture
was centrifuged for 10 min at 12,000 x g, the aqueous phase
was collected, and to this 1 volume of phenol-chloroform (1:1)
was added. After shaking and centrifugation as before, the
aqueous phase was collected and an equal volume of chloro-
form was added. The aqueous phase was collected again after
a further shaking and centrifugation step. DNA was precipi-
tated by the addition of 0.05 volume of 5 M NaCl and 2
volumes of cold 100% ethanol ( - 20°C) and then centrifuged
at 12,000 x g for 20 min. The pellet was dried and dissolved in
100 of TE buffer.
Solutions for spiking of clinical samples. For spiking and
sensitivity determinations, bacteria and DNA from an M.
tuberculosis strain that has eight copies of the insertion ele-
ment IS986 (8) were used. Insertion sequence IS986 is virtually
identical to the IS6110 insertion element (11, 22).
Precautions to prevent contamination. In our laboratory,
prevention of contamination is accomplished by physical sep-
aration of different steps in the PCR procedure, using different
pipettes, and wearing separate coats and gloves in each labo-
ratory. The PCR mix is prepared in one laboratory, where
work is conducted in a safety cabinet to prevent contamination
of the PCR mix by shedding of material from exposed facial
skin or hair. Chemicals for use in the PCR and for the
treatment of clinical samples are weighed in this laboratory on
a balance which is used only for this purpose. Ultrapure water
(Baker, Deventer, The Netherlands) is used to make the
solutions, which are sterilized in this laboratory. The solutions
are stored as aliquots to minimize the number of repeated
samplings. Mycobacterial strains or template DNA is not
allowed in this laboratory. In a second laboratory clinical
samples are treated in a safety cabinet and added to the PCR
mix. If possible, we do not open more than one vial at a time
in this laboratory. Only concentrations of M. tuberculosis DNA
lower than 100 pg/ml are allowed in this room. Chemical
decontamination of surfaces and equipment is done weekly in
both laboratories with 0.5% sodium hypochlorite (15). The
PCR and the detection of PCR products, by agarose gel
electrophoresis and dot blot hybridization, are done in a third
laboratory in a safety cabinet used only for this purpose.
Synthetic oligonucleotides. Lyophilized oligonucleotides
were purchased from Isogen Bioscience (Amsterdam, The
Netherlands). Prior to lyophilization the A260 was determined
and the oligonucleotide solution was aliquoted in 10 vials.
Lyophilized oligonucleotides were kept at - 20°C until use.
The amount of ultrapure water needed to give a 50 ,uM
solution in a vial of lyophilized oligonucleotide was calculated
by using the A260 and the millimolar extinction coefficient of
the oligonucleotide (17). The resulting solution was aliquoted
in volumes of 50 pJ and kept at - 20°C. One vial was kept at
4°C for immediate use.
PCR for clinical samples. Two oligonucleotide primers
within the IS6110 insertion sequence, designated primers Pt8
(5'-GTGCGGATGGTCGCAGAGAT-3') and Pt9 (5'CTCG
ATGCCCTCACGGTTCA-3'), were used for the PCR, result-
ing in a 541-bp PCR fragment (10). The composition of the
PCR mix was 10 mM Tris-HCl (pH 8.3), 50 mM NaCl, 2.0 mM
MgCl2, 0.01% (wt/vol) gelatin, 0.2 mM (each) deoxynucleoside
triphosphates (dATP, dCTP, dGTP, and dUTP), 0.2 puM
(each) primers Pt8 and Pt9, 1 U of Taq polymerase (Perkin-
Elmer Cetus, Norwalk, Conn.), and 0.01 U of UNG, (GIBCO
BRL, Gaithersburg, Md.) per 50-pl reaction volume. The PCR
mix was aliquoted in a final volume of 40 pul per reaction vial
and stored at - 20°C. When a test was performed, the reaction
vials were removed from the freezer and 50 ,ul of mineral oil
(Sigma, St. Louis, Mo.) was added to each vial before the 10-,u
sample was placed under the oil layer. For preparing the PCR
mixes and pipetting the mineral oil, positive displacement
pipette tips (Microman, Gilson, France) were used. For pipet-
ting clinical samples and DNA solutions, we used DNA-PCR
filter tips (Greiner, Nurtingen, Germany). PCR was performed
in a water bath thermocycler (Bio-med 60 processor; Bio-med,
Theres, Germany) or a heating block thermocycler (Gene
ATAQ Controller; Pharmacia LKB, Uppsala, Sweden). The
temperature indicators of the thermocyclers were checked
monthly with an electrical thermometer (51 K/ Thermometer;
Fluke, Everett, Wash.), which in turn was checked twice a year
against an officially calibrated mercury thermometer. The PCR
incubations were as follows: 5 min at 50°C to allow breakdown
of amplicons by UNG, followed by 40 cycles of 1.5 min of
denaturation at 94°C, 2 min of annealing at 65°C, and 3 min of
primer extension at 72°C. If the PCR products were not
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analyzed directly after the final cycle, the vials were incubated
for a minimum of 1 h at 72°C.
The quality of the PCR mix was tested by amplification of a
series of 1,000, 100, 10 and 1 fg of M. tuberculosis DNA per
vial. Ten microliters of TE buffer was tested in duplicate to
provide a negative control for contamination with M. tubercu-
losis DNA during the preparation of the mix. To control for the
activity of the UNG, a vial with 10 ,ul of a 15-pg/pL 541-bp
amplicon solution was amplified in the same assay. This
amplicon solution was prepared by using 1,000 fg of M.
tuberculosis DNA as a template in PCR and subsequently
diluting this PCR product 1,000-fold. The PCR mix was
considered to be of sufficient quality if 10 fg of M. tuberculosis
DNA, corresponding to two bacteria, could be detected and if
the vials containing TE buffer and the vial containing 150 pg of
541-bp amplicon were negative in PCR.
In all PCR series involving clinical samples, positive controls
consisting of a series of vials containing 1,000, 100, 10, and 1 fg
of M. tuberculosis DNA and two vials with TE buffer were
included. Each treated sample from a patient was tested in
triplicate. One part (10 ,ul) was spiked with 10 fg of M.
tuberculosis DNA, and two parts were not spiked. If all three
samples were positive, then the sample was considered posi-
tive. The sample was scored as negative if the nonspiked
reactions were negative and the spiked reaction was positive. If
the results for the nonspiked reactions were ambiguous, the
PCR was repeated. If all three reactions were negative, then
there were inhibitors in the sample. In such a case, the PCR
was repeated with a smaller sample volume; if inhibition
recurred, another DNA extraction method was used; if there
was still inhibition, then a further sample from the patient was
requested.
Detection of amplified DNA. The PCR products were ana-
lyzed by agarose gel electrophoresis on 2% agarose gels (8).
The results were recorded by Bio-print photodocumentation
and when necessary stored in the image storage system (Vil-
ber-Lourmat, Marne-la-Vallee, France).
For comparison of PCR results, the intensity of the PCR
products was compared visually with the intensity of the PCR
products of the positive controls. An intensity equal to or
greater than that of the product of 100 fg of M. tuberculosis
DNA was scored 2+, an intensity between those of the
products of 100 and 10 fg of M. tuberculosis DNA was scored
+, and an intensity less than that of 10 fg of M. tuberculosis
DNA was scored +. For efficiency calculations, the amount of
PCR product was more accurately determined by spot quan-
tification, by interpolation with a standard curve using the
Bio-profile software (Vilber-Lourmat). The standard curve
was constructed employing the amounts of DNA from the
fragments of the HaeIII-digested XX174 replicative form mo-
lecular size marker (New England Biolabs, Beverly, Md.).
The PCR results with clinical samples were confirmed by dot
blot hybridization with a biotin-labeled oligonucleotide probe.
Oligonucleotide labeling with biotin. The oligonucleotide
PtlO (5'-AGCACGAYTCGGAGTGGGCA-3'), which is situ-
ated within the 541-bp fragment and corresponds to bp 134 to
153 of the insertion sequence IS6110 of M. tuberculosis, was tail
labeled at the 3' end of the DNA with biotin-16-dUTP by using
the enzyme terminal transferase (18). Biotin-labeled PtlO was
also commercially obtained (Isogen Bioscience). The biotin
group was covalently attached to the 5' end of the DNA via a
six-carbon spacer arm.
Dot blot hybridization and colorimetric detection. Rein-
forced nitrocellulose membranes (Duralose; Stratagene, La
Jolla, Calif.) were cut into pieces (8 by 12 cm) and presoaked
in water and then in 10x SSC (1 x SSC is 0.15 M NaCl plus
TABLE 1. Efficiency of PCR
Template DNA PCR product
Amt No. of copies No. of molecules of Efficiency(fg) n,., ~Amt (ng) 541-bp amplicon(fg) of IS6110 (10'')
10,000 16,000 758 ± 93 13 0.58
1,000 1,600 426 ± 68 7.2 0.65
100 160 197 ± 50 3.3 0.71
10 16 81±65 1.4 0.77
0.015 M Na-citrate [pH 7.0]). Samples of 5 ,ul of PCR-
amplified DNA were made up to a final volume of 50 [1I in
water and denatured by boiling for 5 min and subsequent
cooling on ice. After the addition of 50 .1I of an ice-cold
solution of 20 x SSC, the mixtures were spotted onto a
presoaked Duralose (Stratagene) membrane by using a dot
blot apparatus (Schleicher-Schiill, Dassel, Germany), and a
vacuum of 60 cm Hg (ca. 800 kPa) was applied. The spots were
washed with 200 p.1 of 1Ox SSC. The DNA was fixed to the
membranes by UV (312 nm) cross-linking at 1/cm2 (Fluo-link
TFL20M; Vilber-Lourmat) or by heating at 120°C for 15 min.
The membranes were sealed in a plastic bag with 5 ml of 5 x
SSC-1% (wt/vol) blocking agent (Boehringer, Mannheim,
Germany)-0.1% (wt/vol) N-laurylsarcosine-0.02% (wt/vol) so-
dium dodecyl sulfate (SDS) and prehybridized at 50°C for 15
min. After the addition of 1 pmol of biotin-labeled PtlO from
either source to the prehybridization mix, the membranes were
incubated at 50°C for another 2 h. The membranes were
washed twice at 50°C for 5 min in 50 ml of 2x SSC-0.1%
(wt/vol) SDS. The membranes were used directly for the
detection of the hybridized probe by incubation with strepta-
vidin-alkaline phosphatase conjugate according to the instruc-
tions of the manufacturer (Boehringer) and scored visually (8).
RESULTS
Specificity, sensitivity, and efficiency of the PCR. PCR using
the primers Pt8 and Pt9 was specific for the M. tuberculosis
complex. No PCR products were found with bacteria or
mycobacteria other than those belonging to this complex. To
determine the sensitivity of the PCR, eight series of 104, 103,
102, 10, and 1 fg of M. tuberculosis DNA were amplified. In all
eight tests 10 fg of DNA, the DNA equivalent of two bacteria
or 16 copies of the IS6110 insertion element, could be detected
by agarose gel electrophoresis. PCRs with 1 fg of DNA were
positive in two of the eight tests.
The amount of PCR product resulting from the different
amounts of template DNA was determined by using the
Bio-profile software (Table 1). The efficiency of the PCR
amplification was calculated by using the following formula: (1
+ x)n = y, where x is the mean efficiency of a cycle, n is the
number of cycles, and y is the amplification factor after n
cycles. The amount of template DNA and amplicon is ex-
pressed as the number of copies of the IS6110 insertion
element. Amplification of 104, 103, 102, and 10 fg of M.
tuberculosis DNA in 40 PCR cycles resulted in mean efficien-
cies of, respectively, 58, 65, 71, and 77% per cycle. Large
quantities of DNA are amplified less efficiently than small
amounts of DNA because the plateau effect occurs earlier for
larger amounts of template DNA.
Detection of amplified DNA. The results obtained by agarose
gel electrophoresis were confirmed by dot blot hybridization
using the enzymatically biotin-labeled probe PtlO. The results
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FIG. 1. Ability of UNG to break down dUTP-containing amplicons
without changing the efficiency of PCR. dUTP-containing amplicons
and M. tuberculosis DNA were used as template in PCR in the absence
(A} and presence (B and C) of 0.01 U of UNG. Lanes 2 to 6, 103, 106,
10 , 1012, and 1015-times-diluted 15-ng/p.l amplicon solution; lanes 8 to
11, 1,000, 100, 10, and 1 fg of M. tuberculosis DNA; lanes 7 and 12, TE
controls; lanes 1 and 13, respectively, 800 and 400 ng of HaeIII-
digested 4X174 DNA (replicative form) as a molecular size marker;
lane 14, 541-bp fragment as a molecular size marker. Amplification
products were detected by agarose gel electrophoresis (A and B) or by
dot blot hybridization (C).
with this oligonucleotide were similar to those with the 188-bp
digoxigenin-labeled fragment, which we used previously (8).
With both probes 100 pg of PCR product could be detected.
Similar results were obtained with the chemically biotin-
labeled PtlO probe (data not shown). The oligonucleotide
probe has the advantage that the hybridization time can be
reduced from the 16 h required for the 188-bp probe to 2 h.
Pre-PCR amplicon degradation. The most likely cause of
false-positive PCR results is contamination with amplicons
from previous PCRs. After using the primer set INS1 and INS2
for a year, we noticed 245-bp amplicons in negative controls.
Contamination was due to the presence of amplicons, not M.
tuberculosis complex bacteria or DNA (8). We replaced the
primers INS1 and INS2 with Pt8 and Pt9, and we used dUTP
instead of dTTP to make amplicons degradable by UNG.
These maneuvers did not affect the overall efficiency of our
PCR (data not shown).
To demonstrate the gravity of amplicon contamination we
tested 10 plA of 1,000-fold serial dilutions of a 15-ng/pl 541-bp
amplicon solution in PCR (Fig. 1A). This amplicon solution
was prepared by using 1,000 fg of M. tuberculosis DNA as a
template in a PCR. We chose to start with a 1,000-fold dilution
since 10 of a 100-fold dilution of the 541-bp amplicon
solution could contain enough template DNA (2 fg) to give a
positive reaction in PCR, due to the amplification of M.
tuberculosis DNA. Figure 1A shows that 10 ,ul of a 15-ng/Iu1
amplicon solution can still be amplified in PCR, even following
a 109-fold dilution. This solution contains 0.15 fg of amplicon.
The minimal amount of UNG necessary to break down
contaminating amplicons was investigated by amplification of
10 ,u of the amplicon dilutions mentioned above in the
presence of 0.5, 0.2, 0.1, 0.05, and 0.01 U of UNG. Panels B
and C of Fig. 1 show that 0.01 U of UNG was able to break
down 150 pg of 541-bp amplicons. The use of UNG did not
affect the sensitivity of the PCR, as shown in Fig. 1A and B
where the amplicon bands in lanes 8, 9, and 10 are of equal
intensity. We performed PCR with 1,000, 100, 10, and 1 fg of
M. tuberculosis DNA in the absence and presence of UNG.
The same sensitivity was seen in both PCRs.
Stability of the PCR mix. For routine diagnosis it is neces-
sary to prepare a batch of ready-for-use PCR vials and to test
the quality of the batch before using it for clinical samples. We
found it convenient to make batches of 200 vials. We consider
the batch of sufficient quality if 10 fg of M. tuberculosis DNA
can be amplified, resulting in a visible band in agarose gel
electrophoresis, if 150 pg of 541-bp amplicon can be degraded,
and if TE controls are negative.
We tested the stability of the PCR mix at different temper-
atures. We kept mixes at -20 or +4°C for 12 weeks, 18 or 37°C
for up to 1 week and performed a PCR with 1,000, 100, and 10
fg of M. tuberculosis DNA. The quality of PCR mixes that had
been stored for 12 weeks at - 20°C was the same as that of
freshly prepared mixes. PCR mixes were stable at 4°C for 1
week, after which the quality of the mix decreased: 10 fg of M.
tuberculosis DNA could not be detected. The stability of the
PCR mixes stored at 20°C (room temperature) and 37°C
deteriorated within 24 h (results not shown). These experi-
ments show that mixes can be stored for at least 3 months in
the freezer and up to 1 week on ice.
The effect of repeated thawing and freezing on the stability
of the PCR mix was also tested. Thawing occurred at room
temperature over 30 min, during which time the contents of
the vial were at 20°C for about 10 min. After three cycles of
thawing and freezing, the quality of the mix was unaffected, but
it deteriorated after four or more cycles (results not shown).
This means that an accidental thawing is not harmful for the
PCR mix.
Sensitivity of PCR for clinical samples. To determine the
detection limit of the PCR in clinical samples, we divided
samples into four portions and spiked three portions with
different amounts of M. tuberculosis bacteria (1,000, 100, and
10 per portion) before sample treatment. Our samples were
four sputum samples (1 ml per portion), one liver biopsy
sample (10 mg per portion), and one feces sample (600 ,ul per
portion) from patients suffering from diseases other than
tuberculosis and one blood sample (600 RI per portion) from a
healthy individual. PCRs were performed with 10-pI portions
(1/10 of the volume) of the treated sample. To detect the
presence of inhibitors, 10 p1 of the treated nonspiked sample
was tested in the presence of 10 fg of M. tuberculosis DNA. In
all cases the spiked DNA could be detected, indicating that
PCR was not inhibited. In the liver biopsy sample, feces, and
two sputum samples the detection limit was 10 M. tuberculosis
bacteria per reaction vial. In the other two sputum samples and
the blood the detection limit was one bacterium per reaction
vial (results not shown).
PCR results compared with those of culture and ZN stain-
ing. Culture provides the "gold standard" for the diagnosis of
infections with M. tuberculosis. We have tested 218 clinical
specimens from patients suspected of having tuberculosis.
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TABLE 2. Comparison of the PCR results of clinical samples from patients suspected of tuberculosis with results of culture and ZN staining'
No. of samples with indicated culture result
Sample source(s) PCR result Positive Negative Total no. tested
ZN+ ZN- ZN+ ZN-
Sputum from:
Thailand Positive 35 12 2 12 61
Negative 5b 0 0 20 25
The Netherlands Positive 26 2 1 1 30
Negative 3c 0 0 20 23
Cerebrospinal fluid Positive 1 1 0 1 3
Negative 0 0 0 12 12
Pleural fluid, fistula fluid, pus Positive 1 2 0 0 3
Negative 1d 0 0 11 12
Biopsy Positive 2 1 2 1 6
Negative 3" 0 0 15 18
Blood Positive 0 0 0 1 1
Negative 0 0 0 13 13
Feces Positive 0 0 0 0 0
Negative 0 0 0 6 6
"Six sputum samples from Thailand, one biopsy sample, and one feces sample contained inhibiting components.
"One Mycobacteriunm fortuitum, one Mycobacterium chelonae, and three unidentified mycobacterial strains were cultured.
One Mycobacterilum avium and two unidentified mycobacterial strains were cultured.
" Mycobacteriunm gordoniae was cultured.
"M. av'ium was cultured in all cases.
Specimens were obtained from a wide variety of sites, and the
results are shown in Table 2. One sputum sample from a
patient from The Netherlands was positive by PCR but nega-
tive by ZN staining and culture. Since bronchoalveolar lavage
fluid obtained from this patient was positive both by ZN
staining and by culture, it is highly probable that the patient
had tuberculosis. The clinical samples other than sputa were
obtained from patients suspected of having tuberculosis who
had a variety of underlying conditions such as other lung
diseases, AIDS, or cancer. When the PCR result was positive
and the results ofZN staining and/or culture were negative, the
clinical picture corroborated the PCR results and the patients
responded to treatment for tuberculosis.
DISCUSSION
Amplicon contamination. False-positive reactions are a ma-
jor problem with PCR methods for the detection of the M.
tuberculosis complex. After using the primer set INSI and
INS2 for 1 year, we noticed that negative controls were positive
in PCR, because of the presence of amplicons in the reaction
vial (8). PCR with 10 p.1 of a 10"-times-diluted 15-ng/pl 541-bp
amplicon solution, which is about 0.15 fg or 250 amplicon
molecules, still gives a clearly visible band in an agarose gel.
This means that an aerosol droplet of this solution with a
volume of 10 6 Il1 can be diluted at least 100 times and can still
cause a false-positive reaction. To prevent amplicon contami-
nation, we replaced the primers INSI and INS2 with Pt8 and
PT9 and simultaneously introduced the use of dUTP instead of
dTTP to make the amplicons degradable by UNG (10).
Neither of these measures affected the efficiency of the PCR.
The use of 0.01 U of UNG was sufficient to break down 150 pg
of 541-bp amplicon, which is more than enough since this is
about 106 times more than the amount of amplicon needed in
PCR to get an intensity comparable to that of a false-positive
negative control when UNG is omitted in the PCR mix.
During a training course five scientists were instructed in the
technique of PCR for M. tuberculosis and the measures needed
to avoid contamination. They were asked to perform PCRs
without UNG (but with dUTP instead of dTTP), and already
after the second PCR two had false-positive results. Thus, the
amplicons may be spread by the operator despite these pre-
cautions. These findings show that false-positive reactions due
to the spread of M. tuberculosis DNA can also be caused by the
investigator. This poses a serious problem and suggests that
stringent attention to matters of detail is necessary to prevent
contamination with amplicons or DNA carried by laboratory
workers and that workers in PCR should not combine their
work with isolation of M. tuberculosis DNA nor with restriction
fragment length polymorphism analysis.
An alternative to the pre-PCR enzymatic amplicon degra-
dation method is the post-PCR photochemical method. We
prefer the former since the large concentrations of isopsoralen
that are needed in the post-PCR photochemical method for
inactivation of small and GC-rich amplicons can reduce the
activity of Taq polymerase (14); moreover, the isopsoralen is
mutagenic.
Inhibition. To detect false-negative reactions due to the
presence of substances that inhibit Taq polymerase, we tested
clinical samples in PCR in the presence of 10 fg of M.
tuberculosis DNA. This approach gives one semiquantitative
datum regarding the amount of M. tuberculosis in the clinical
sample by comparison with a series of amplified M. tuberculosis
DNA. Quantitation of the number of M. tuberculosis bacteria
in the clinical sample can be relevant for follow-up of patients
on drug therapy to detect drug resistance at an early stage.
Inhibition was demonstrated in six sputum samples from
Thailand. We are investigating whether the inhibition is caused
by the storage vials, the transport of the samples, or storage at
- 20°C, since the sputum samples from the hospitals in The
Netherlands, which were usually tested while fresh, did not
show inhibition of the PCR.
Treatment of clinical samples. Most or all of the inhibiting
substances in clinical samples are effectively removed by the
DNA purification method with guanidinium thiocyanate and
diatoms (1). This method is also applicable to lymphocyte
fractions from blood but not to whole blood, since hemoglobin
will inhibit the PCRs. The isolation of the lymphocyte fraction
must be done with a sample less than 24 h old. Blood which is
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older or is frozen cannot be used because of the lysis of
erythrocytes which releases hemoglobin. The method of choice
for isolation of DNA from blood is proteinase K treatment
followed by phenol-chloroform extraction, since this method
gives good results, is simple, and can also be used on frozen
blood samples. A further advantage of this DNA isolation
procedure over the method using guanidinium thiocyanate and
diatoms is that larger volumes of blood can be used, improving
the chances of detection of infection, since the DNA binding
capacity of diatoms is limiting. We also used proteinase K
treatment followed by phenol-chloroform extraction on feces,
since this method proved to be superior to the guanidinium
thiocyanate method. One of seven feces samples still interfered
in the PCR.
PCR results with clinical samples. The results with PCR
accorded well with the bacteriological data, except for Thai
sputa which were negative by ZN staining and culture. At the
Tuberculosis Division in Bangkok, ZN staining and culture
were done without concentrating the sample during sputum
decontamination, leading to a lower sensitivity. This was
probably the reason for the high number (12 of 32) of sputum
samples that were positive by PCR but negative by ZN staining
and culture. The PCR results corresponded well with the
culture results, except for one cerebrospinal fluid sample, one
tissue biopsy sample, and one blood sample that were positive
in PCR but negative in ZN staining and culture. These samples
were obtained from patients for whom clinical data supported
the diagnosis of tuberculosis and who responded to treatment
for tuberculosis. The data suggest that PCR can be a useful
tool for the diagnosis of extrapulmonary tuberculosis.
Mycobacteria other than tuberculosis. The increased inci-
dence of mycobacterial infections other than tuberculosis
emphasizes the need for correct species identification. Twelve
samples (6%) contained mycobacteria other than tuberculosis
(Table 2). None of these samples were positive in the PCR for
M. tuberculosis complex, which demonstrates the specificity of
our PCR.
Recommendations. In conclusion, PCR is the method of
choice for the diagnosis of tuberculosis in cases where the
suspicion is high but ZN staining is negative. When the sample
is positive in ZN staining, PCR permits distinction between M.
tuberculosis complex and other mycobacterial infections. In
comparison with our previously described PCR for the detec-
tion of M. tuberculosis complex (8), the approach described
here has the following advantages: (i) the risk of amplicon
contamination is removed by the use of UNG and the incor-
poration of dUTP instead dYTP, thereby reducing false-
positive reactions, resulting in increased specificity of the PCR
for clinical samples; (ii) costs are lower since fewer reactions
are needed to test one sample, the chemically biotin-labeled
probe is cheaper than the digoxigenin labeled probe (8), and
the hybridization process takes only 2 h; (iii) by conducting
quality control of the PCR procedure and apparatus, the
number of failures is reduced; and (iv) contamination with
DNA is reduced by limiting the amount of DNA in the sample
preparation room. The detection limit for M. tuberculosis
bacteria in clinical samples has been improved 10-fold by
concentrating the samples by centrifugation whenever possi-
ble. Stringent attention to matters of detail is necessary to
prevent contamination by DNA carried by laboratory workers.
Quality control of the PCR mix and the performance of the
amplification itself is mandatory if routine PCR is to replace
culture for the diagnosis of tuberculosis.
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